MedPath

Long-term Effects of Combined Balance and Brisk Walking in Parkinson's Disease

Not Applicable
Completed
Conditions
Parkinson Disease
Interventions
Behavioral: Flexibility and strengthening exercise
Behavioral: Combined balance and brisk walking training
Registration Number
NCT04665869
Lead Sponsor
The Hong Kong Polytechnic University
Brief Summary

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized with both clinical motor and non-motor features, as well as decrease in balance performance and walking endurance. The non-motor symptoms such as depression, anxiety, sleep disturbance and fatigue wound impose negative impacts on the quality of life of the individuals with PD. Aerobic endurance training can improve physical capacity and reduce those non-motor symptoms such as mood and sleep disorders. Based on the results of our recent pilot study, brisk walking is a safe and moderate-level aerobic walking exercise for improving walking capacity in the PD population up to 6 week after treatment ended. Community-based balance training could also enhance balance performance and dual-task gait performance up to 12-month follow-up for people with PD. The primary purpose of this proposed study is to investigate the short- and long-term effects of a 6-month balance and brisk walking programme in alleviating non-motor and motor symptoms in people with PD. The secondary objective is to examine the short- and long-term effects of a 6-month balance and brisk walking program on enhancing walking capacity, balance performance, and quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Parkinson disease diagnosed by neurologist with Hoehn & Yahr stage 2 or 3
  • Having a 30-meter walking ability
Exclusion Criteria
  • Significant neurological condition (other than Parkinson's disease)
  • Musculoskeletal conditions affecting gait, balance or functions
  • Had received deep brain stimulation surgery
  • Cognitive impairment with Montreal Cognitive Assessment score <24
  • Present with on-off motor fluctuations.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Flexibility and strengthening exerciseFlexibility and strengthening exercise1. Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session 2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session 3. Participants practice own flexibility and strengthening exercise 2-3 times/week (to aim at 150 min of exercise per week)
Combined balance and brisk walking trainingCombined balance and brisk walking trainingWeek1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session 2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session 3. Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)
Primary Outcome Measures
NameTimeMethod
Movement Disorder Society Unified Parkinson Disease Rating Scale Part III (MDS-UPDRS-III) score1 year

This score consists of 18 items in 33 questions examining the motor and functional capacity of people with Parkinson's disease by the assessor. Each question will be rated from 0 (normal) to 4 (severe). The MDS-UPDRS-III score ranges from 0 to 132, with higher scores indicating more severe motor and functional impairments

Movement Disorder Society Unified Parkinson Disease Rating Scale Part I (MDS-UPDRS-I) score1 year

This score assesses the non-motor aspects of experiences of daily living in people with Parkinson's disease with a total of 13 questions. The score will be administered by assessor asking participants about their behaviors and non-motor symptoms such as cognitive impairment, hallucination, depressive and anxious mood, sleep, pain, urinary and constipation problems, and fatigue etc. Each question will be rated from 0 (normal) to 4 (severe). The MDS-UPDRS-I score ranges from 0 to 52, with higher scores indicating more severe non-motor impairment.

Secondary Outcome Measures
NameTimeMethod
Mini-Balance Evaluation Systems Test (mini-Best) total score1-year

To evaluate dynamic balance in four domains: anticipatory postural adjustments, postural reactions, sensory integration and gait stability. The mini-BEST total score ranges from 0 to 28, with a higher score indicates better dynamic balance.

Six-minute walking test (6MWT) distance1 year

The maximum walking distance covered during a validated six-minute walk test (6MWT) to document participants' aerobic endurance level and walking capacity

Single-task timed-up-and-go (TUG) time1 year

The single-task gait performance measured by the time taken to complete 3-meter timed-up-and-go (TUG) test

Five-times-sit-to-stand (FTSTS) time1 year

The composite lower limb strength measured by the time taken to complete 5 repetitions of sitting to standing

Gait cycle measures by 2-minute Instrument Walk Test using mobile sensors in both comfortable and fast walking speed1 year

Spatial, gait phase, spatiotemporal and asymmetric walking variables such as gait speed, cadence, stride length, arm swing angle and velocity, and trunk movement angle and velocity will be measured by Mobility Lab system.

Activities-specific Balance Confidence (ABC) Scale score1 year

The ABC score will be used to measure the participants' perceived level of balance confidence in 16 indoor and outdoor activities. Each activity is rated from 0-100 (0 indicates no confidence and 100 indicates full confidence, total score=1600). The total score is converted into percentage score ranging from 0 to 100%, with a higher ABC score indicating a higher level of balance confidence.

Parkinson Disease Questionnaire-39 (PDQ-39) summary index score1 year

It is a health-related quality-of-life outcome measure that contains 39 self-reported items on eight domains, i.e.: mobility \[#1-10\], activities of daily living \[#11-16\], emotional well-being \[#17-22\], stigma \[#23-26\], social support \[#27-29\], cognition \[#30-33\], communication \[#34-36\], and body discomfort \[#37-39\]. The PDQ-39 has been translated into Chinese and validated for local use. Each item is scored on 5-point Likert-type scales ranging from 0 (never), 1 (occasionally), 2 (sometimes), and 3 (often) to 4 (always) based on their perception on the item over the past month. The PDQ-39 total score is 156 and the PDQ-39 summary index is created by summing all eight of the PDQ-39 domains and standardizing the score on a scale of 0-100%. A lower PDQ-39 summary index score reflects a better health-related quality-of-life.

Injurious fall rate1 year

The injurious fall rate (times of injurious fall per year per person) of each group at treatment completion and 6-month follow-up will be calculated with the following formula:

Number of injurious fall events X12 / (Number of months spent to collect injurious fall data X number of subjects)

A lower injurious fall rate indicates a better effect on injurious fall reduction.

Dual-task timed-up-and-go (DTUG) time1 year

The dual-task gait performance measured by the time taken to complete 3-meter timed-up-and-go test with serial subtraction

Non-Motor Symptoms Scale for Parkinson's Disease (NMSS) total score1 year

The Non-Motor Symptoms Scale is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The NMSS total score ranges form 0 to 360, with a higher score indicates worse PD non-motor symptoms.

Pittsburgh Sleep Quality Index (PSQI)1 year

The Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month. A total score of "5" or greater is indicative of poor sleep quality.

Fall risk1 year

The risk of falling of each group will be determined by the ratio of non-fallers to fallers at treatment completion and 6-month follow-up. A lower risk ratio indicates a lower risk of falling.

Fall rate1 year

The fall rate (times of fall per year per person) of each group at treatment completion and 6-month follow-up will be calculated with the following formula:

Number of fall events X12 / (Number of months spent to assemble fall data X number of subjects)

A lower fall rate indicates a better effect on fall reduction.

Injurious fall risk1 year

The risk of injurious falling of each group at treatment completion and 6-month follow-up will be determined by the ratio of injurious non-fallers to injurious fallers. A lower injurious risk ratio indicates a lower risk of injurious falling.

Trial Locations

Locations (1)

The Hong Kong Polytechnic University

🇭🇰

Hong Kong, Nothing Selected, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath